LTZ Therapeutics is focused on developing innovative myeloid engager therapeutics aimed at enhancing anti-tumor immunity through a unique three-pronged approach. This strategy is grounded in reverse translational science and the emerging biology of the tumor microenvironment, which allows the company to identify unmet clinical needs and novel therapeutic targets. Their Myeloid Engager Platform is designed to directly engage myeloid cells with target cells, activating mechanisms such as phagocytosis to eliminate cancer cells. This platform not only stimulates myeloid cells to release minimal cytokines and chemokines, which help reprogram the immunosuppressive tumor microenvironment, but also promotes the cross-presentation of tumor neoantigens to activate tumor-specific T cells, thereby supporting durable anti-tumor immune responses.

The Myeloid Engager Platform is characterized as a proprietary, fully humanized bispecific antibody system that enhances the innate immune response while ensuring safety through controlled cytokine release. By activating myeloid cells and natural killer (NK) cells, the platform facilitates potent killing of cancer cells and enhances the presentation of antigens to T cells. This dual activation not only improves the efficacy of the immune response but also aims to reprogram myeloid cells into a more pro-inflammatory state, which is crucial for combating tumor growth and fostering immunological memory. Overall, LTZ Therapeutics is leveraging the therapeutic potential of myeloid cells to develop novel immunotherapies that address significant challenges in cancer treatment.

United States

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

LTZ Therapeutics

Company Details